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and overcome the effects of under-valuation of vaccina-
tion on a global scale.
METHODS: Estimates of vaccine-preventable cases
worldwide, vaccine coverage levels, disease incidence,
vaccine costs and cost-effectiveness were obtained
through in a four-stage process. First, an electronic 
document search was conducted. Second, government
documents and academic publications were reviewed.
Third, academic and government experts in vaccine cost-
effectiveness were contacted to obtain several estimates.
Fourth, the epidemiological and economic data obtained
from the ﬁrst two stages were converted to the following
common units: US$, LYS, deaths, QALYs, and DALYs, 
to allow for further economic analyses of the value of 
vaccination.
RESULTS: Disease: Direct or indirect savings Smallpox
$300 million in direct costs per year; Polio US$13.6B in
total savings worldwide; Measles US$10 per DALY
Cholera $770 million; Malaria $100B GDP lost per year
in Africa; MMR $100 million direct medical costs; DTPa
$23.6B direct and indirect costs; Hib $5B direct, $12B
indirect costs in US.
CONCLUSIONS: Vaccines are unquestionably one of 
the most cost-effective public health measures available,
yet they are undervalued and underutilized throughout
the world. It is important for international agencies, gov-
ernments, and health policy makers to keep this preven-
tive measure in the spotlight. It is important to remind
parents, the general population, and health care providers
worldwide to take advantage of this life-saving measure
so that no one will suffer diseases that can so easily be
prevented.
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AN EPIDEMIOLOGICAL EXAMINATION OF
MEDICATION RESOURCE USE AND COSTS
AMONG THE INSURED ELDERLY
Alemayehu B,Aubert RE, Epstein R
Merck-Medco Managed Care, LLC, Franklin Lakes, NJ, USA
OBJECTIVE: The objective of this study is to describe
the demographic proﬁles, drug costs, medication utiliza-
tion, and chronic disease characteristics of the insured
elderly population in the United States, with particular
emphasis on those with high outpatient drug expenses.
METHODS: Prescription claims data from the Merck-
Medco National Probability Sample Database, a 10%
stratiﬁed random sample of continuously eligible lives
covered by Merck-Medco during 2000, was used for the
analysis.
RESULTS: 495,260 insured elderly (age > = 65) were
identiﬁed in the sample database. Demographically,
49.7% were female, the mean age was 75.8 years (sd 7.5)
and they were predominantly from Middle Atlantic
(23.5%) and South Atlantic (23.3%) regions of the
country. Seventy-seven percent ﬁlled one or more pre-
scriptions (range 1–480 prescriptions per person per year)
and this number varied signiﬁcantly by age and region.
Fifty-ﬁve percent of elderly patients ﬁlled prescriptions for
conditions related to the cardiovascular system, 22.0%
for the endocrine, 19.4% for the GI, 19.0% for the CNS
and 9.0% for the respiratory system. In terms of expen-
diture (expressed in Average Wholesale Price), 32.5% of
the total expenditure was for cardiovascular medications,
10.4% for GI, 5.6% for endocrine and 3.5% for respi-
ratory medications. Overall, 10.4% of the elderly had a
medication expenditure of $4,000 or more, 38.8% had
expenditures between $1,000 and $4,000, 27.7% had
cost that averaged $443 and the remaining 23.0% 
had no drug expenditure during 2000. Regression model
analyses revealed that increasing age (p-value = 0.04),
female gender (p-value < 0.01), and residence in Middle
Atlantic, New England or Paciﬁc regions (p-value < 0.01)
were signiﬁcant and independent risk factors for increas-
ing medication costs.
CONCLUSIONS: There are demographic and chronic
conditions associated with higher medication utilization
that are important to consider when developing a policy
for national prescription drug coverage for the elderly.
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Prescription drug coverage issues have generated consid-
erable attention within health care and political agendas.
To allocate scarce resources efﬁciently, it is important to
identify the characteristics of individuals with the highest
level of out-of-pocket expenditures for prescription 
medications.
OBJECTIVE: To identify factors explaining the variance
associated with individual out-of-pocket prescription
drug costs.
METHODS: We analyzed data from the household com-
ponent and event ﬁles of the 1996 Medical Expenditure
Panel Survey (MEPS), with brand-generic status informa-
tion obtained from MULTUM®. Of the 22,601 individ-
uals, 14,015 (62%) incurred prescription expenditures.
Out-of-pocket prescription costs were regressed on demo-
graphic factors, socioeconomic factors, perceived health
status, type of health insurance coverage, perceived access
to care, prescription drug characteristics, and health 
care cost data. Person level weights were included in the
regression model. Variance estimation was performed to
adjust for the complex survey design employed by MEPS.
RESULTS: The mean out-of-pocket prescription drug
cost was $166 (se = 4.61). Minorities had lower out-of-
pocket costs ($117, se = 7.87) compared to Caucasians
($175, se = 5.05), whereas uninsured consumers had
greater out-of-pocket costs ($181, se = 20.29) compared
to consumers with private insurance ($156, se = 4.76).
Signiﬁcant (alpha = 0.05) predictors with positive coefﬁ-
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cients included: age, poverty status, total number of 
prescriptions, and total out-of-pocket non-prescription
health care costs. Signiﬁcant predictors with negative
coefﬁcients included: education, race/ethnicity, covered
prescription costs and percent of prescription drug expen-
ditures for generic drugs. The overall model was signiﬁ-
cant (p < 0.001) with an R2 = 0.44.
CONCLUSIONS: Out-of-pocket prescription drug costs
were associated with several sociodemographic and
health care cost variables. However, no signiﬁcant asso-
ciations were found between health status and perceived
access to care variables. These ﬁndings suggest that eco-
nomic factors are important when assessing out-of-pocket
expenditures but other variables such as prescription drug
characteristics should not be omitted.
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HOW MUCH DOES IT COST TO DIE OF THAT?
EFFECTS OF AGE AND CHRONIC ILLNESS ON
HEALTHCARE COSTS AT THE END OF LIFE
Mapel DW, Frost FJ, Paine S, Hurley JS, Petersen HV
Lovelace Respiratory Research Institute, Albuquerque, NM,
USA
OBJECTIVE: Healthcare utilization during the last year
of life has traditionally comprised 27% to 31% of the
total Medicare budget, but knowledge of factors affect-
ing terminal costs is limited. We examined the effects of
age, gender, ethnicity, and chronic illness on medical costs
in the last year of life.
METHODS: This was a retrospective cohort analysis of
longitudinal utilization data in a regional health mainte-
nance organization (HMO). Study subjects were HMO
members (2312) who died between January 1, 1996 and
December 31, 1998. Healthcare utilization during the 12
months prior to death was captured from administrative
claims and matched to cause of death on the death 
certiﬁcate. We also determined chronic illnesses present
using claims data and compared this to cause of death on
the death certiﬁcate.
RESULTS: Mean total cost in the last year of life was
$37,736 (+$21,692), with two-thirds of the costs attrib-
uted to inpatient care ($23,321 +$8,748) per patient).
Costs varied widely by age at time of death, with mean
total costs highest among persons age 65 to 70. Costs fell
rapidly after age 70. Total costs increased linearly with
the number of chronic illnesses, which varied signiﬁcantly
with age. Patients with renal failure and complicated 
diabetes had terminal costs substantially higher than 
did patients with most other chronic illnesses; costs for
patients who died with chronic dementia were lower than
average. Sex and ethnicity were not signiﬁcant factors
after adjustment for age. Cost analyses based on the cause
of death on death certiﬁcates underestimated the impact
of several major illnesses.
CONCLUSIONS: Healthcare costs at the end of life vary
widely by age and the number and type of chronic ill-
nesses in the year prior to death. Cause of death listed on
death certiﬁcates does not accurately reﬂect the impact of
chronic illness on terminal costs.
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A DECISION ANALYSIS MODEL FOR
SCREENING OF HEREDITARY
HEMOCHROMATOSIS
Greenwood TG, Pathak D
The Ohio State University, Columbus, OH, USA
OBJECTIVES: This study examines screening alternatives
for detection of hereditary hemochromatosis (HH). The
objectives included: (1) To evaluate three screening alter-
natives (no screening, phenotype screening, and genotype
screening) in a cost-effectiveness analysis for HH; and, (2)
To serve as a model for genetic diseases.
METHODS: The decision analysis using Data 3.5 soft-
ware was conducted for both cost-effectiveness and cost-
utility analyses. A hypothetical cohort of 10,000 white
males between thirty and thirty-nine years old was the
identiﬁed as the model population because of its high HH
prevalence rate. Each screening alternative correlated 
to a decision tree branch, which further subdivided into
branches depending upon treatment decisions. The costs
data were conservatively estimated using 2001 United
States Medicare charge data. Testing protocols were
based on established methods previously used in a cost-
effectiveness study by Adams and Valberg in 1999. The
utility values were estimated using experts’ judgments on
the Health Utilities Index.
RESULTS: The results of the cost-effectiveness analysis
indicated that genotype testing was the dominant strat-
egy. The marginal cost-effectiveness of genetic testing
found that an extra $219.85 per case would identify
another thirteen cases. A sensitivity analysis found the
genetic testing cost as the threshold value. The cost-utility
analysis, using quality-adjusted life years (QALY) as a
measure of effectiveness, indicated that genotype testing
was the dominant strategy. The marginal cost/QALY
found that an additional $85.48 per case identiﬁed 10
new cases.
CONCLUSIONS: Genetic testing for HH represents an
opportunity for widespread screening. The high preva-
lence rate and beneﬁt of early diagnosis and treatment
make HH an ideal screening target. The infrastructure for
genetic testing must be built before widespread screening
could occur; thus, the policy-makers and insurance com-
panies should be educated about cost-effectiveness studies
which demonstrate the merits of detecting genetic diseases
prior to symptom manifestation.
